|
10.01.2025 09:09:10
|
IO Biotech Completes Phase 2 Enrollment Ahead Of Schedule For IO102-IO103 Cancer Vaccine Trial
(RTTNews) - IO Biotech, Inc. (IOBT), a clinical-stage biopharmaceutical company, Thursday, announced that it has completed enrollment ahead of its schedule in its Phase 2 basket trial of lead investigational therapeutic cancer vaccine candidate, IO102-IO103.
In the phase II basket study, IO102-IO103 is being tested in combination with Merck's (MRK) blockbuster cancer drug, KEYTRUDA, administered both before (neoadjuvant) and after (adjuvant) surgery with the goal of curing patients with resectable melanoma or squamous cell carcinoma of the head and neck.
The study has enrolled 93 patients across sites in the United States, Europe, and Australia, with initial results anticipated in 2025.
A global phase III clinical trial for IO102-IO103, in combination with Keytruda, in patients with advanced melanoma is also underway, with data due in the first half of 2025.
IOBT closed Wednesday's trading at $0.85, down 3.38%.
Analysen zu IO Biotech Inc Registered Shs
Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ LPL Finance
✅ Blackstone
✅ Ares Management
👉🏽 https://bxplus.ch/bx-musterportfolio/
Inside Trading & Investment
Mini-Futures auf SMI
Inside Fonds
Aktien in diesem Artikel
| IO Biotech Inc Registered Shs | 0.90 | -0.13% |
|
Meistgelesene Nachrichten
Top-Rankings
Börse aktuell - Live Ticker
SMI geht fester aus dem Handel -- US-Handel endet mit Aufschlägen -- DAX schliesst nach neuem Rekord freundlich -- Börsen in Fernost letztlich mehrheitlich im PlusDer heimische Aktienmarkt zeigte sich am Donnerstag im Plus. Der deutsche Aktienmarkt notierte höher. Die US-Börsen schlossen höher. Asiens Börsen verbuchten am Donnerstag überwiegend Gewinne.
finanzen.net News
| Datum | Titel |
|---|---|
|
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
|
{{ARTIKEL.NEWS.BODY.TITEL}} |